Compare LyondellBasell Industries NV (LYB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Novartis AG — how do they compare? LyondellBasell Industries NV trades at $60.34 (market cap $18.89B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 14.5× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Novartis AG for 82 Days on average.
| LYB | NVS | |
|---|---|---|
Market Cap | $18.89B | $274.00B |
Volume | 2,621,859 | 1,852,137 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $168.62 |
52-Week Low | $42.28 | $121.80 |
Typical Hold Time | 87 Days | 82 Days |
Enterprise Value | $30.48B | $315.32B |
Dividend Yield | 4.72% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $60.36, up 2.42% today, with a bearish technical signal but mixed fundamental outlook. Revenue declined to $30.15B in 2025, resulting in a net loss of $745M, though recent quarters show earnings beats. The stock is supported by a 45% analyst buy rating and a $69.38 consensus price target, but faces headwinds from cyclical chemical demand and high debt levels.
LYB offers potential upside from operational recovery and dividend yield, but risks include volatile earnings, margin pressure, and industry competition. The stock remains a speculative play on chemical sector stabilization, with investor sentiment divided between near-term challenges and long-term value.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
